Royal Sense Ltd
Incorporated in 2023, Royal Sense Ltd specializes in medical device and pharmaceutical trading.[1]
- Market Cap ₹ 34.9 Cr.
- Current Price ₹ 65.2
- High / Low ₹ 256 / 61.0
- Stock P/E 5.14
- Book Value ₹ 82.6
- Dividend Yield 0.00 %
- ROCE 26.1 %
- ROE 21.0 %
- Face Value ₹ 10.0
Pros
- Stock is trading at 0.79 times its book value
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Half Yearly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|
| 18 | 62 | 103 | 106 | |
| Sales growth | +247% | +67% | +28% | |
| 16 | 53 | 92 | 95 | |
| Operating Profit | 2 | 9 | 11 | 11 |
| OPM % | 13% | 14% | 11% | 10% |
| 0 | 0 | 0 | 0 | |
| Interest | 0 | 0 | 1 | 2 |
| Depreciation | 0 | 0 | 0 | 0 |
| Profit before tax | 2 | 9 | 10 | 9 |
| Tax % | 28% | 27% | 28% | |
| 2 | 6 | 7 | 7 | |
| EPS in Rs | 3.24 | 12.74 | 13.36 | 12.69 |
| Dividend Payout % | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 28% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -15% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | -69% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 20% |
| Last Year: | 21% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 | |
|---|---|---|---|---|
| Equity Capital | 5 | 5 | 5 | 5 |
| Reserves | 13 | 23 | 35 | 39 |
| 2 | 3 | 13 | 22 | |
| 1 | 5 | 8 | 11 | |
| Total Liabilities | 21 | 36 | 61 | 77 |
| 0 | 2 | 2 | 2 | |
| CWIP | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 |
| 20 | 33 | 59 | 75 | |
| Total Assets | 21 | 36 | 61 | 77 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|
| -4 | 1 | -13 | |
| -1 | -2 | -0 | |
| 13 | 3 | 5 | |
| Net Cash Flow | 9 | 2 | -8 |
| Free Cash Flow | -4 | -0 | -14 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | -144% | 21% | -110% |
Ratios
Consolidated / View Standalone
| Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|
| Debtor Days | 66 | 86 | 101 |
| Inventory Days | |||
| Days Payable | |||
| Cash Conversion Cycle | 66 | 86 | 101 |
| Working Capital Days | 187 | 86 | 126 |
| ROCE % | 35% | 26% |
Insights
In beta| Mar 2024 | Mar 2025 | |
|---|---|---|
| Geographic Presence (States/UTs) count ・Standalone data |
|
|
| Permanent Employees count ・Standalone data |
||
| New Products Launched count ・Standalone data |
||
| Satisfied Customers count ・Standalone data |
||
| Total Product Portfolio count ・Standalone data |
||
| US FDA Approvals Obtained count ・Standalone data |
||
Extracted by Screener AI
Documents
Announcements
-
Board Meeting Intimation for Intimation Of Board Meeting To Be Held On 24Th November, 2026
- Board meeting on 24 Nov 2026 to consider raising funds via inter-corporate loans/borrowings.
-
Board Meeting Outcome for Outcome Of Board Meeting Held On 17Th November, 2026- Withdrawal Application Of Merger
- Board withdrew merger scheme with TTG Innovations on 17 November 2026.
-
Unaudited Financial Results For The Half Year Ended 30Th September, 2026
- Board approved unaudited H1 FY2026-27 results on 14 Nov 2026; auditor issued unmodified review reports.
-
Board Meeting Outcome for Outcome Of Board Meeting - Declaration Of Unaudited Financial Results For The Half Year Ended 30Th September, 2026
- Board approved unaudited financial results for half-year ended 30 September 2026 on 14 November 2026.
-
Board Meeting Intimation for Prior Intimation Of Board Meeting To Be Held On 14Th November, 2026
- Board meeting on 14 Nov 2026 to approve half-year unaudited standalone and consolidated results.
Annual reports
-
Annual Report 2026
from bse
-
Annual Report 2025
from bse
-
Annual Report 2024
from bse
Business Overview:[1][2]
RSL deals in Advanced medical devices, pharmaceuticals, diagnostics, and offers surgical solutions. It provides hospitals, laboratories, clinics, and institutions
with products like surgical accessories, instruments, equipment, consumables,
reagents, diagnostic kits, and disposable
medical supplies